Pretreatment of human mesenchymal stem cells with pioglitazone improved efficiency of cardiomyogenic transdifferentiation and cardiac function

Stem Cells

Volumn 29, Issue 2, 2011, Pages 357-366

  Shinmura, Daisuke ^a   Togashi, Ikuko ^a   Miyoshi, Shunichiro ^a   Nishiyama, Nobuhiro ^a   Hida, Naoko ^a   Tsuji, Hiroko ^a   Tsuruta, Hikaru ^a   Segawa, Kaoru ^a   Tsukada, Yuiko ^a   Ogawa, Satoshi ^a   Umezawa, Akihiro ^b  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

Author keywords

Cardiac; Cell culture; Cell transplantation; Immune deficient models; Somatic stem cells; Stem cell plasticity; Transdifferentiation

Indexed keywords

2 CHLORO 5 NITROBENZANILIDE; PIOGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL SURVIVAL; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MESENCHYMAL STEM CELL; NONHUMAN; NUDE RAT; RAT; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADULT; ANIMALS; BONE MARROW CELLS; CELL DIFFERENTIATION; CELLS, CULTURED; HEART; HEART VENTRICLES; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MYOCARDIAL INFARCTION; MYOCYTES, CARDIAC; PPAR GAMMA; RATS; RATS, NUDE; THIAZOLIDINEDIONES; VENTRICULAR FUNCTION, LEFT;

RATTUS;

EID: 79952129848     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.574     Document Type: Article

References (32)

1. Boheler KR, Czyz J, Tweedie D et al. Differentiation of pluripotent embryonic stem cells into cardiomyocytes. Circ Res 2002;91:189-201. (Pubitemid 34875673)
2. Okita K, Ichisaka T, Yamanaka S. Generation of germline-competent induced pluripotent stem cells. Nature 2007;448:313-317. (Pubitemid 47080336)
3. Andrews PW. From teratocarcinomas to embryonic stem cells. Philos Trans R Soc Lond B Biol Sci 2002;357:405-417. (Pubitemid 34489857)
4. Masaki H, Ishikawa T, Takahashi S et al. Heterogeneity of pluripotent marker gene expression in colonies generated in human iPS cell induction culture. Stem Cell Res 2007;1:105-115. (Pubitemid 351726532)
5. Takeda Y, Mori T, Imabayashi H et al. Can the life span of human marrow stromal cells be prolonged by bmi-1, E6, E7, and/or telomerase without affecting cardiomyogenic differentiation? J Gene Med 2004;6:833-845.
6. Beltrami A, Barlucchi L, Torella D et al. Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell 2003;114:763-776. (Pubitemid 37186770)
7. Tateishi K, Ashihara E, Honsho S et al. Human cardiac stem cells exhibit mesenchymal features and are maintained through Akt/GSK-3beta signaling. Biochem Biophys Res Commun 2007;352:635-641. (Pubitemid 44880302)
8. Nishiyama N, Miyoshi S, Hida N et al. The significant cardiomyogenic potential of human umbilical cord blood-derived mesenchymal stem cells in vitro. Stem Cells 2007;25:2017-2024. (Pubitemid 47258179)
9. Hida N, Nishiyama N, Miyoshi S et al. Novel cardiac precursor-like cells from human menstrual blood-derived mesenchymal cells. Stem Cells 2008;26:1695-1704.
10. Okamoto K, Miyoshi S, Toyoda M et al. 'Working' cardiomyocytes exhibiting plateau action potentials from human placenta-derived extraembryonic mesodermal cells. Exp Cell Res 2007;313:2550-2562.
11. Tsuji H, Miyoshi S, Ikegami Y, et al. Xenografted human amniotic membrane-derived mesenchymal stem cells are immunologically tolerated and transdifferentiated into cardiomyocytes. Circ Res 2010;106:1613-1623.
12. Gnecchi M, He H, Liang O et al. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat Med 2005;11:367-368. (Pubitemid 40562318)
13. Gojo S, Gojo N, Takeda Y et al. In vivo cardiovasculogenesis by direct injection of isolated adult mesenchymal stem cells. Exp Cell Res 2003;288:51-59.
14. Kocher AA, Schuster MD, Szabolcs MJ et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med 2001;7:430-436. (Pubitemid 32298545)
15. Ikegami Y, Miyoshi S, Nishiyama N et al. Serum-independent cardiomyogenic transdifferentiation in human endometrium-derived mesenchymal cells. Artif Organs 2010 (in press).
16. Gilbertson JR. Cardiac Muscle in Lipid Metabolism in Mammals. Vol. 1. New York: Plenum Press, 1977.
17. Puigserver P, Spiegelman BM. Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): Transcriptional coactivator and metabolic regulator. Endocr Rev 2003;24:78-90. (Pubitemid 36223280)
18. Matsuura K, Wada H, Nagai T et al. Cardiomyocytes fuse with surrounding noncardiomyocytes and reenter the cell cycle. J Cell Biol 2004;167:351-363. (Pubitemid 39435077)
19. Kliewer SA, Umesono K, Noonan DJ et al. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992;358:771-774.
20. Tang WH, Francis GS, Hoogwerf BJ et al. Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol 2003;41:1394-1398. (Pubitemid 36439002)
21. Yamakawa K, Hosoi M, Koyama H et al. Peroxisome proliferator-activated receptor-gamma agonists increase vascular endothelial growth factor expression in human vascular smooth muscle cells. Biochem Biophys Res Commun 2000;271:571-574. (Pubitemid 30444669)
22. Yamauchi T, Kamon J, Waki H et al. The mechanisms by which both heterozygous peroxisome proliferator-activated receptor gamma (PPARgamma) deficiency and PPARgamma agonist improve insulin resistance. J Biol Chem 2001;276:41245-41254.
23. Iwaki M, Matsuda M, Maeda N et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003;52:1655-1663. (Pubitemid 36792453)
24. Kadowaki T. Insights into insulin resistance and type 2 diabetes from knockout mouse models. J Clin Invest 2000;106:459-465. (Pubitemid 30666378)
25. Matsushita K, Wu Y, Okamoto Y et al. Local renin angiotensin expression regulates human mesenchymal stem cell differentiation to adipocytes. Hypertension 2006;48:1095-1102. (Pubitemid 44772713)
26. Tsuji H, Miyoshi S, Ikegami Y et al. Xenografted human amniotic membrane-derived mesenchymal stem cells are immunologically tolerated and transdifferentiated into cardiomyocytes. Circ Res 2010;106:1613-1623.
27. Shiomi T, Tsutsui H, Hayashidani S et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 2002;106:3126-3132. (Pubitemid 35440299)
28. Frantz S, Hu K, Widder J et al. Peroxisome proliferator activated-receptor agonism and left ventricular remodeling in mice with chronic myocardial infarction. Br J Pharmacol 2004;141:9-14. (Pubitemid 38241158)
29. Shake JG, Gruber PJ, Baumgartner WA et al. Mesenchymal stem cell implantation in a swine myocardial infarct model: Engraftment and functional effects. Ann Thorac Surg 2002;73:1919-1925; discussion: 1926.
30. Hare JM, Traverse JH, Henry TD et al. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol 2009;54:2277-2286.
31. Chen SL, Fang WW, Ye F et al. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am J Cardiol 2004;94:92-95. (Pubitemid 38813459)
32. Li J, Lang MJ, Mao XB et al. Antiapoptosis and mitochondrial effect of pioglitazone preconditioning in the ischemic/reperfused heart of rat. Cardiovasc Drugs Ther 2008;22:283-291.